Hims & Hers Health (NYSE:HIMS) Releases Earnings Results, Misses Estimates By $0.44 EPS

Hims & Hers Health (NYSE:HIMS) issued its earnings results on Monday. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44), FiscalAI reports. The company had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.88 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.

Hims & Hers Health Stock Up 3.0%

HIMS traded up $0.85 during trading on Monday, reaching $29.12. 56,288,845 shares of the stock traded hands, compared to its average volume of 33,104,969. The stock has a market cap of $6.64 billion, a price-to-earnings ratio of 57.10, a price-to-earnings-growth ratio of 3.85 and a beta of 2.43. Hims & Hers Health has a fifty-two week low of $13.74 and a fifty-two week high of $70.43. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The stock’s 50-day simple moving average is $22.56 and its two-hundred day simple moving average is $29.75.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. Barclays lifted their target price on Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, March 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a report on Friday, March 27th. Zacks Research upgraded Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. TD Cowen lowered their price target on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, March 27th. Finally, Leerink Partners lifted their price target on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. Four equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $31.86.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers raised its outlook for FY 2026 revenue to $2.8 billion-$3.0 billion, ahead of the $2.7 billion consensus, suggesting management sees continued strong demand for its telehealth and digital care offerings.
• Positive Sentiment: The company also guided Q2 2026 revenue to $680 million-$700 million, above Wall Street’s $643.8 million estimate, which may help offset concerns from the latest earnings miss.
• Neutral Sentiment: Hims & Hers continues to expand its digital healthcare platform with new care offerings, including labs, menopause and testosterone care, along with broader international and GLP-1-related initiatives. Article: Hims & Hers Expands Digital Healthcare Platform via New Care Offerings
• Negative Sentiment: First-quarter results disappointed, with EPS of -$0.40 versus expectations for $0.04 and revenue of $608.1 million versus $616.9 million expected, which explains the pressure on the stock.
• Negative Sentiment: Investor reaction has been cautious after the earnings release, with coverage noting that shares are falling because the quarter came in below Wall Street expectations. Article: Hims & Hers Stock Sinks. Why Earnings Offered Wall Street A Big Surprise.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock in a transaction on Monday, April 20th. The stock was sold at an average price of $29.96, for a total transaction of $588,564.20. Following the completion of the sale, the chief financial officer owned 262,954 shares of the company’s stock, valued at approximately $7,878,101.84. This trade represents a 6.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 9,463 shares of Hims & Hers Health stock in a transaction on Monday, April 20th. The shares were sold at an average price of $30.00, for a total value of $283,890.00. Following the sale, the insider directly owned 299,368 shares of the company’s stock, valued at approximately $8,981,040. The trade was a 3.06% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 204,857 shares of company stock worth $5,285,706 in the last ninety days. Company insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

A number of institutional investors have recently bought and sold shares of the company. Captrust Financial Advisors boosted its position in Hims & Hers Health by 3.1% during the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock valued at $728,000 after purchasing an additional 443 shares during the last quarter. Binnacle Investments Inc acquired a new stake in Hims & Hers Health during the third quarter valued at $28,000. Amundi boosted its position in Hims & Hers Health by 5.3% during the second quarter. Amundi now owns 10,296 shares of the company’s stock valued at $489,000 after purchasing an additional 522 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Hims & Hers Health by 273.7% during the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after purchasing an additional 687 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its position in Hims & Hers Health by 4.9% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 16,059 shares of the company’s stock valued at $521,000 after purchasing an additional 756 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.